Globus Medical, Inc. (FRA:GM0N)
Germany · Delayed Price · Currency is EUR | Market Cap | 9.13B +39.1% |
| Revenue (ttm) | 2.69B +23.5% |
| Net Income | 508.85M +216.2% |
| EPS | 3.72 +221.1% |
| Shares Out | n/a |
| PE Ratio | 17.95 |
| Forward PE | 15.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 69.40 |
| Previous Close | 70.44 |
| Day's Range | 69.40 - 69.40 |
| 52-Week Range | 44.40 - 83.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Globus Medical
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractu... [Read more]
Financial Performance
In 2025, Globus Medical's revenue was $2.94 billion, an increase of 16.65% compared to the previous year's $2.52 billion. Earnings were $537.87 million, an increase of 422.28%.
Financial numbers in USD Financial StatementsNews
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
AUDUBON, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30...
Globus Medical price target lowered to $100 from $115 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $100 from $115 and keeps a Buy rating on the shares as part of a broader…
Globus Medical price target lowered to $115 from $120 at RBC Capital
RBC Capital analyst Shagun Singh lowered the firm’s price target on Globus Medical (GMED) to $115 from $120 and keeps an Outperform rating on the shares as part of a…
BMO Capital starts Globus Medical at Outperform on earnings power
As previously reported, BMO Capital initiated coverage of Globus Medical (GMED) with an Outperform rating and $94 price target The market continues to underappreciate the earnings power of the fully…
Globus Medical initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Globus Medical (GMED) with an Outperform rating and $94 price target
Globus Medical price target lowered to $80 from $95 at Stifel
Stifel analyst Thomas Stephan lowered the firm’s price target on Globus Medical (GMED) to $80 from $95 and keeps a Hold rating on the shares. 2026 revenue expectations are being…
Globus Medical price target lowered to $100 from $115 at Piper Sandler
Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Globus Medical (GMED) to $100 from $115 and keeps an Overweight rating on the shares. The firm is updating…
Globus Medical price target raised to $117 from $114 at Needham
Needham raised the firm’s price target on Globus Medical (GMED) to $117 from $114 and keeps a Buy rating on the shares.
Globus Medical price target lowered to $103 from $104 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Globus Medical (GMED) to $103 from $104 and keeps an Overweight rating on the shares. The firm notes Globus…
Globus Medical reports Q1 EPS $1.12, consensus 92c
Reports Q1 revenue $759.85M, consensus $740.83M. “We’re off to a strong start in 2026 with 27% overall revenue growth and record first quarter earnings. Organic revenue grew over 13%, driven…
Globus Medical raises FY26 EPS view to $4.70-$4.80 from $4.40-$4.50
Consensus $4.47. Backs FY26 revenue view $3.18B-$3.22B, consensus $3.2B. The company said, “The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to…
Globus Medical Earnings Call Transcript: Q1 2026
Q1 2026 delivered 27% revenue growth and 64.7% non-GAAP EPS growth, driven by strong U.S. and international spine, trauma, and enabling technologies. Margin expansion and operational efficiency led to raised EPS guidance, while Nevro is expected to recover in H2 2026.
Globus Medical Earnings release: Q1 2026
Globus Medical released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Globus Medical Quarterly report: Q1 2026
Globus Medical has published its Q1 2026 quarterly earnings report on May 7, 2026.
Globus Medical Reports First Quarter 2026 Results
AUDUBON, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March ...
Globus Medical Proxy statement: Proxy filing
Globus Medical filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Globus Medical Proxy statement: Proxy filing
Globus Medical filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Globus Medical Schedules First Quarter Earnings Release and Conference Call
AUDUBON, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 3...
Globus Medical Announces Board Departure
AUDUBON, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical I...
Globus Medical assumed with an Overweight at Wells Fargo
Wells Fargo assumed coverage of Globus Medical (GMED) with an Overweight rating and $104 price target The firm is maintaining the current rating, price target and estimates. Published first on…
Globus Medical price target raised to $104 from $98 at Wells Fargo
Wells Fargo raised the firm’s price target on Globus Medical (GMED) to $104 from $98 and keeps an Overweight rating on the shares following quarterly results. At 33.9% consolidated EBITDA…
Globus Medical price target raised to $115 from $105 at Truist
Truist analyst Richard Newitter raised the firm’s price target on Globus Medical (GMED) to $115 from $105 and keeps a Buy rating on the shares. The firm cites the company’s…
Globus Medical price target raised to $115 from $112 at Canaccord
Canaccord raised the firm’s price target on Globus Medical (GMED) to $115 from $112 and keeps a Buy rating on the shares. The firm said the company posted an impressive…
Globus Medical price target raised to $123 from $118 at Barclays
Barclays analyst Matt Miksic raised the firm’s price target on Globus Medical (GMED) to $123 from $118 and keeps an Overweight rating on the shares following the Q4 report. The…
Globus Medical reports Q4 EPS $1.28, consensus 96c
Reports Q4 revenue $826.4M, consensus $803.29M. “Momentum built throughout 2025 accelerated in the fourth quarter, capping off a strong finish to the year with double-digit sales and earnings growth,”...